These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 19191301

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ, Li JJ.
    Clin Chim Acta; 2014 Apr 20; 431():148-53. PubMed ID: 24518357
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD.
    J Clin Lipidol; 2014 Apr 20; 8(3):256-64. PubMed ID: 24793346
    [Abstract] [Full Text] [Related]

  • 5. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, Junien C, Varret M, Boileau C, Benlian P, Rabès JP.
    Hum Mutat; 2005 Nov 20; 26(5):497. PubMed ID: 16211558
    [Abstract] [Full Text] [Related]

  • 6. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
    Abifadel M, Pakradouni J, Collin M, Samson-Bouma ME, Varret M, Rabès JP, Boileau C.
    Expert Opin Ther Pat; 2010 Nov 20; 20(11):1547-71. PubMed ID: 20849207
    [Abstract] [Full Text] [Related]

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.
    Nutr Metab Cardiovasc Dis; 2011 Nov 20; 21(11):835-43. PubMed ID: 21943799
    [Abstract] [Full Text] [Related]

  • 8. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
    Leren TP.
    Clin Genet; 2004 May 20; 65(5):419-22. PubMed ID: 15099351
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J, Wang LY, Liu S, Wang XM, Yong Q, Yang Y, DU LP, Pan XD, Wang X, Jiang ZS.
    Chin Med J (Engl); 2010 May 05; 123(9):1133-8. PubMed ID: 20529551
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C.
    Nat Genet; 2003 Jun 05; 34(2):154-6. PubMed ID: 12730697
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recent patents on PCSK9: a new target for treating hypercholesterolemia.
    Li H, Li H, Ziegler N, Cui R, Liu J.
    Recent Pat DNA Gene Seq; 2009 Jun 05; 3(3):201-12. PubMed ID: 19601924
    [Abstract] [Full Text] [Related]

  • 17. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
    Abifadel M, Rabès JP, Jambart S, Halaby G, Gannagé-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Aydénian H, Junien C, Munnich A, Boileau C.
    Hum Mutat; 2009 Jul 05; 30(7):E682-91. PubMed ID: 19319977
    [Abstract] [Full Text] [Related]

  • 18. [Monogenic hypercholesterolemias: new genes, new drug targets].
    Mandel'shtam MIu, Vasil'ev VB.
    Genetika; 2008 Oct 05; 44(10):1309-16. PubMed ID: 19062528
    [Abstract] [Full Text] [Related]

  • 19. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M.
    Am J Cardiovasc Drugs; 2011 Jun 01; 11(3):145-52. PubMed ID: 21619378
    [Abstract] [Full Text] [Related]

  • 20. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA.
    Curr Opin Investig Drugs; 2009 Sep 01; 10(9):938-46. PubMed ID: 19705336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.